DC4 Stock Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$122.92 |
| 52 Week High | US$131.88 |
| 52 Week Low | US$71.33 |
| Beta | 1.21 |
| 1 Month Change | -4.01% |
| 3 Month Change | 5.33% |
| 1 Year Change | 9.26% |
| 3 Year Change | 41.29% |
| 5 Year Change | 346.66% |
| Change since IPO | 6,046.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DC4 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.7% | -0.6% | 1.8% |
| 1Y | 9.3% | -9.5% | 2.2% |
Return vs Industry: DC4 exceeded the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: DC4 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| DC4 volatility | |
|---|---|
| DC4 Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DC4 has not had significant price volatility in the past 3 months.
Volatility Over Time: DC4's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9,550 | Kevin Sayer | www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
DexCom, Inc. Fundamentals Summary
| DC4 fundamental statistics | |
|---|---|
| Market cap | €49.65b |
| Earnings (TTM) | €506.63m |
| Revenue (TTM) | €3.39b |
98.0x
P/E Ratio14.7x
P/S RatioIs DC4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DC4 income statement (TTM) | |
|---|---|
| Revenue | US$3.62b |
| Cost of Revenue | US$1.33b |
| Gross Profit | US$2.29b |
| Other Expenses | US$1.75b |
| Earnings | US$541.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 1.37 |
| Gross Margin | 63.19% |
| Net Profit Margin | 14.95% |
| Debt/Equity Ratio | 117.7% |
How did DC4 perform over the long term?
See historical performance and comparison